In vivo immunomodulatory effects of clozapine in schizophrenia

Schizophrenia Research

Volumn 26, Issue 2-3, 1997, Pages 221-225

  Maes, Michael ^a,b   Bosmans, Eugene ^c   Kenis, Gunter ^d   De Jong, Raf ^d   Smith, Ronald S ^e   Meltzer, Herbert Y ^b  

^a Clinical Research Center for Mental Health of Antwerp   (Belgium)

^b VANDERBILT UNIVERSITY   (United States)

^c Eurogenetics   (Belgium)

^d AZ ^*  (Belgium)

^e Sierra Pacific Seminars   (United States)

Author keywords

CC16; CD8; Cytokines; Interleukin 1; Interleukin 6; Schizophrenia

Indexed keywords

CD8 ANTIGEN; CELL PROTEIN; CLOZAPINE; CYTOKINE; IMMUNOMODULATING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; NEUROLEPTIC AGENT; TRANSFERRIN RECEPTOR;

ADULT; ARTICLE; CLARA CELL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOMODULATION; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIGENS, CD8; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MEMBRANE PROTEINS; NEUROIMMUNOMODULATION; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-2; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TRANSFERRIN; SCHIZOPHRENIA;

EID: 0030838833     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(97)00057-1     Document Type: Article

References (22)

1. American Psychiatric Association, 1987. Diagnostic and Statistical Manual of Mental Disorders. The American Psychiatric Association, Washington, DC.
2. Dierynck I., Bernard A., Roels H., De Ley M. Potent inhibition of both interferon-γ production and biologic activity by the Clara cell protein CC16. Am. J. Respir. Cell. Mol. Biol. 12:1995;205-210.
3. Ganguli R., Yang Z., Shurin G., Chengappa K.N.R., Brar J.S., Gubbi A.V., Rabin B.S. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. 51:1994;1-10.
4. Howell, D.C. (Ed.), 1982. Statistical Methods for Psychology. Duxbury Press, Boston, pp. 378-399.
5. Katila H., Appelberg B., Hurme M., Rimon R. Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr. Res. 12:1994;29-34.
6. Licinio J., Krystal J.H., Seibyl J.P., Altemus M., Charney D.S. Elevated central levels of interleukin-2 in drug-free schizophrenic patients. Schizophr. Res. 44:1991;372.
7. Linker-Israeli M., Hyun S., Ozeri-Chen T., Wallace D.J., Banks K., Klinenberg J.R. Elevated in vivo and in vitro secretion of CD8-alpha molecules in patients with systemic lupus erythematosus. J. Immunol. 152:1994;3158-3167.
8. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 29:1995;141-152.
9. Maes M., Bosmans E., Ranjan R., Vandoolaeghe E., Meltzer H.Y., De Ley M., Berghmans R., Stans G., Desnyder R. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1-receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr. Res. 21:1996;39-50.
10. Maes M., Delanghe J., Ranjan R., Meltzer H.Y., Desnyder R., Cooreman W., Scharpe S. The acute phase protein response in schizophrenia, mania and major depression: effects of psychotropic drugs. Psychiatr. Res. 66:1997;1-11.
11. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 89:1994;346-351.
12. Maes M., Meltzer H.Y., Buckley P., Bosmans E. Plasma soluble interleukin-2 and transferrin receptor in schizophrenia and depression. Eur. Arch. Psychiatry Clin. Sci. 244:1995;325-329.
13. Muller N., Hofschuster E., Ackenheil M., Eckstein R. T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy. Acta Psychiatr. Scand. 87:1993;66-71.
14. Naudin J., Mege J.L., Azorin J.M., Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr. Res. 20:1996;269-273.
15. Pollmacher T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 16:1996;403-409.
16. Rapaport M.H., McAllister C.G., Pickar D., Nelson D.L., Paul S.M. Elevated levels of soluble interleukin-2 receptors in schizophrenia. Arch. Gen. Psychiatry. 46:1989;291-292.
17. Rhoades H.M., Overall J.E. The semistructured BPRS interview and rating guide. Psychopharmacol. Bull. 10:1988;101-104.
18. Sirota P., Schild K., Elizur A., Djaldetti M., Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog. NeuroPsychopharmacol. Biol. Psychiatry. 19:1995;75-83.
19. Smith R.S. Is schizophrenia caused by excessive production of interleukin-2 and interleukin-2 receptors by gastrointestinal lymphocytes? Med. Hypotheses. 34:1991;225-229.
20. Smith R., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med. Hypotheses. 45:1995;135-141.
21. Surman O.S. Possible immunological effects of psychotropic medication. Psychosomatics. 34:1993;139-143.
22. Suzuki E., Shintani F., Kanba S., Asai M., Nakaki T. Induction of interleukin-1β and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain. Neurosci. Lett. 215:1996;201-204.